Skip to main content

SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen 50 micrograms, powder and suspension for suspension for injection (GSK, NZ)​

Section 19A approved medicine
SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen 50 micrograms, powder and suspension for suspension for injection (GSK, NZ)​
Section 19A approval holder
GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481
Phone
1800 033 109
Approved until
Status
Current
Medicines in short supply/unavailable
SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection - ARTG 289257
Indication(s)

SHINGRIX is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in:

  • adults 50 years of age or older;
  • adults 18 years of age or older at increased risk of HZ.
Images
Picture of SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen 50 micrograms, powder and suspension for suspension for injection - carton

Help us improve the Therapeutic Goods Administration site